Results for “packalen” 3 found
Mikko Packalen, with co-authors, fellow in Progress Studies, Associate Professor of Economics, University of Waterloo, to improve science, in particular to study superior methods for improving systems of science citation. Here is some previous MR coverage of his work.
Daniel Gallardo Albarrán, post doc at Wageningen University, Netherlands, for historical research on European and other policy responses to plagues.
Anna Steingold, Barnard College, general career support and to investigate small business successes and failure in New York City.
Fasih Zulfiqar, Karachi, Pakistan, home schooled and #1 economics student on the Pakistan national exam. For the study of economics in college and general career support.
Dylan White, living in Dubai, philosophy and tutor background, to start a podcast on travel and tourism during pandemic times.
Sarvasv Kulpati, Singapore, about to start UC Berkeley (if possible), interested in education and technology.
Bekhzod Khoshimov, Ph.d. candidate at the University of Wisconsin, Madison, Wisconsin School of Business, for the study of entrepreneurship and to develop his podcast matters related to political economy and also Uzbekistan and Russia. Here is his interview with James Robinson.
We demonstrate empirically that measures of novelty are correlated with but distinct from measures of scientific impact, which suggests that if also novelty metrics were utilized in scientist evaluation, scientists might pursue more innovative, riskier, projects.
That is from Jay Bhattacharya and Mikko Packalen in a new NBER working paper and scientific innovation and stagnation.
They point out that Eugene Garfield, the scientist behind the development of citation count, did not think it should be used to evaluate individual scientists. Overall, citations encourage too much work in crowded, “approaching peak” areas, rather than developing new ideas. In lieu of citations, the authors suggest using textual analysis to determine how much a paper is building on new ideas rather than on already intensively explored ideas.
That is a new paper by Mikko Packalen and Jay Bhattacharya, here is the abstract:
The National Institutes of Health (NIH) plays a critical role in funding scientific endeavors in biomedicine that would be difficult to finance via private sources. One important mandate of the NIH is to fund innovative science that tries out new ideas, but many have questioned the NIH’s ability to fulfill this aim. We examine whether the NIH succeeds in funding work that tries out novel ideas. We find that novel science is more often NIH funded than is less innovative science but this positive result comes with several caveats. First, despite the implementation of initiatives to support edge science, the preference for funding novel science is mostly limited to work that builds on novel basic science ideas; projects that build on novel clinical ideas are not favored by the NIH over projects that build on well-established clinical knowledge. Second, NIH’s general preference for funding work that builds on basic science ideas, regardless of its novelty or application area, is a large contributor to the overall positive link between novelty and NIH funding. If funding rates for work that builds on basic science ideas and work that builds on clinical ideas had been equal, NIH’s funding rates for novel and traditional science would have been the same. Third, NIH’s propensity to fund projects that build on the most recent advances has declined over the last several decades. Thus, in this regard NIH funding has become more conservative despite initiatives to increase funding for innovative projects.